Viatris faces risks from competition, government price reductions, tender systems, macroeconomic conditions (inflation, exchange rates, geopolitical events), supply chain disruptions, regulatory changes, clinical trial outcomes, manufacturing facility issues, legal proceedings (including litigation, government inquiries, and patent challenges), data security breaches, and third-party relationships. The success of acquired projects and the fair value of contingent consideration are also uncertain.
Financial Upside
Viatris has a diverse product portfolio, a global supply chain, and significant liquidity. Recent acquisitions (Idorsia) and licensing agreements (Lexicon) aim to expand the product pipeline and potentially increase revenue and profitability. Divestitures (OTC, women's healthcare, API) generate proceeds and potentially reduce future liabilities. A share repurchase program is in place.
